Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 1, 2020, Pages

  Vasconcellos, Vitor F ^a   Marta, Guilherme N ^a   da Silva, Edina MK ^b   Gois, Aecio FT ^c   de Castria, Tiago B ^a   Riera, Rachel ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c Centro de Estudos de Saúde Baseada em Evidências e Avaliação Tecnológica em Saúde   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; IRINOTECAN; PACLITAXEL; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; COMORBIDITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INTERVENTION STUDY; NON SMALL CELL LUNG CANCER; OPEN STUDY; OVERALL SURVIVAL; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; FEMALE; LUNG TUMOR; MALE; META ANALYSIS; NAUSEA; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NAUSEA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING;

EID: 85077765203     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009256.pub3     Document Type: Review

References (51)

1. Cai X, Chen P, Yin X, Li Q. Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2002;5(6):427-8. x-wiley/crsRef/12608504
2. Chen YM, Perng RP, Tsai CM, Whang-Peng J. A phase II randomized study of paclitaxel plus carboplatin or cisplatin against chemo-naive inoperable non-small cell lung cancer in the elderly. Journal of Thoracic Oncology 2006;1(2):141-5. x-wiley/crsRef/12608506
3. Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M, et al. Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer 2017;83:302–12. x-wiley/crsRef/12608508
4. Fossella F, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. Journal of Clinical Oncology 2003;21(16):3016-24. x-wiley/crsRef/12608510
5. Mazzanti P, Massacesi C, Rocchi MB, Mattioli R, Lippe P, Trivisonne R, et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003;41(1):81-9. x-wiley/crsRef/12608512
6. Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Annals of Oncology 2002;13(10):1539-49. x-wiley/crsRef/12608514
7. Saad AS, Ghali RR, Shawki MA. A prospective randomized controlled study of cisplatin versus carboplatin-based regimen in advanced squamous nonsmall cell lung cancer. Journal of Cancer Research and Therapeutics 2017;13(2):198-203. x-wiley/crsRef/12608516
8. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New England Journal of Medicine 2002;346(2):92-8. x-wiley/crsRef/12608518
9. Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001;92(10):2639-47. x-wiley/crsRef/12608520
10. Yan D, Wang G, Zhang G, Hu C. A randomized phase II trial of paclitaxel in combination chemotherapy with platinum in the treatment of non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2001;4(3):188-90. x-wiley/crsRef/12608522
11. Zatloukal P, Petruzelka L, Zemanová M, Kolek V, Skricková J, Pesek M, et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003;41(3):321-31. x-wiley/crsRef/12608524
12. Billingham L, Gaunt P, Jarrett HW, Dunlop D, Thompson D, O’Byrne KJ, et al. Quality of life in advanced non-small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients. Thorax 2011;66:A41. x-wiley/crsRef/12608526
13. Moro-Sibilot D, Audigier-Valette C, Merle P, Quoix E, Souquet PJ, Barlesi F, et al. Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: comparison of two chemotherapy regimens (IFCT-0702: a randomized phase 3 final results study). Lung Cancer 2015;89(2):139-45. x-wiley/crsRef/12608528
14. Schuette WH, Gröschel A, Sebastian M, Andreas S, Müller T, Schneller F, et al. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clinical Lung Cancer 2013;14(3):215-23. x-wiley/crsRef/12608530
15. Smit E, Moro-Sibilot D, de Castro Carpeño J, Lesniewski-Kmak K, Aerts J, Villatoro R, et al. Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: analysis from the European FRAME study. Lung Cancer 2016;92:35-40. x-wiley/crsRef/12608532
16. Sun X, Zheng Y. Cisplatin or carboplatin for advanced non–small cell lung cancer?. Journal of Thoracic Oncology 2014;9(9):e70. x-wiley/crsRef/12608534
17. Tiseo M, Ardizzoni A, Boni L. First-line chemotherapy treatment of advanced non–small-cell lung cancer. Does cisplatin versus carboplatin make a difference?. Journal of Thoracic Oncology 2014;9(11):e82. x-wiley/crsRef/12608536
18. von Verschuer U, Schnell R, Tessen HW, Eggert J, Binninger A, Spring L, et al. Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer – final results from the prospective German TLK cohort study. Lung Cancer 2017;112:216-24. x-wiley/crsRef/12608538
19. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. Journal of the National Cancer Institute 2007;99(11):847-57.
20. Baggstrom M, Stinchcombe T, Fried D, Poole C, Hensing T, Socinski M. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. Journal of Thoracic Oncology 2007;2(9):845-53.
21. de Souza JA, Hunt B, Asirwa FC, Adebamowo C, Lopes G. Global health equity: cancer care outcome disparities in high-, middle-, and low-income countries. Journal of Clinical Oncology 2016;34(1):6-13. [PUBMED: 26578608]
22. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer 2009;45(2):228-47.
23. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2018;68:394–424.
24. McMaster University (developed by Evidence Prime, Inc.). GRADEpro Guideline Development Tool. Hamilton (ON).: McMaster University (developed by Evidence Prime, Inc.), 2015. Available at gradepro.org.
25. Green S, Benedetti J, Crowley J. Clinical trials in oncology. 2nd Edition. Boca Raton, FL: Chapman & Hall/CRC, 2003.
26. Gridelli C, Rossi A, Carbone DP, Guarize J, Karachaliou N, Mok T, et al. Non-small-cell lung cancer. Nature Reviews Disease Primers 2015;1(May 21;1:15009):1:16. [DOI: 10.1038/nrdp.2015.9]
27. Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, Ellis PM, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology 2017;35(30):3484-515. [PUBMED: 28806116]
28. Higgins JPT, Green S, editor(s). Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
29. Ho GY, Woodward N, Coward JIG. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Critical Reviews in Oncology/Hematology 2016;102:37-46. [DOI: 10.1016/j.critrevonc.2016.03.014]
30. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 2004;22(19):3852-9.
31. Jiang J, Liang X, Zhou X, Huang R, Chu Z. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007;57(3):348-58.
32. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. KEYNOTE-024 Investigators. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New England Journal of Medicine 2016;375(19):1823-33.
33. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. KEYNOTE-189 Investigators. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. New England Journal of Medicine 2018;378(22):2078-92. [DOI: 10.1056/NEJMoa1801005]
34. Lisberg A, Garon EB. Does platinum-based chemotherapy still have a role in first-line treatment of advanced non-small-cell lung cancer?. Journal of Clinical Oncology 2019;37(7):529-36. [PUBMED: 30676857]
35. National Cancer Institute. Common toxicity criteria. ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf (accessed 26 June 2013).
36. Noone AM, Cronin KA, Altekruse SF, Howlader N, Lewis DR, Petkov VI, et al. Cancer incidence and survival trends by subtype using data from the Surveillance Epidemiology and End Results program, 1992-2013. Cancer Epidemiology, Biomarkers & Prevention 2017; Vol. 26, issue 4:632-41. [DOI: 10.1158/1055-9965.EPI-16-0520]
37. NSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311(7010):899-909.
38. O’Dwyer PJ, Calvert AH. Platinum analogs. In: DeVita VT, Lawrence TS, Rosenberg SA editor(s). Cancer: principles and practice of oncology. 10th Edition. Philadelphia: Lippincott Williams & Wilkins, 2015:199-208.
39. Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W, et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 2004;43(1):83-91.
40. Parmar MKB, Valter T, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
41. Perez-Ramirez C, Canadas-Garre M, Molina MA, Robles AI, Faus-Dader MJ, Calleja-Hernandez MA. Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer. Mutation Research 2017;771:32-58. [PUBMED: 28342452]
42. Pocock S, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
43. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology 2010;21(9):1804-9.
44. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
45. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. New England Journal of Medicine 2006;355(24):2542-50.
46. Scagliotti V, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology 2008;26:3543-51.
47. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org..
48. Sobin LH, Wittekind C. Union for International Cancer Control (UICC), TNM Classification of Malignant Tumours. 6th Edition. Vol. 1, New York: Wiley-Liss, 2002.
49. Vasconcellos VF, Colli LM, Awada A, de Castro Junior G. Precision oncology: as much expectations as limitations. ecancermedicalscience 2018; Vol. 12:ed86. [PUBMED: 30679954]
50. Wright J, Boddy A, Highley M, Fenwick J, McGill A, Calvert A. Estimation of glomerular filtration rate in cancer patients. British Journal of Cancer 2001;84(4):452-9.
51. de Castria TB, da Silva EM, Gois AF, Riera R. Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD009256.pub2]